Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bone morphogenetic protein receptor type 2 (BMPR2) is a critical transmembrane serine/threonine kinase belonging to the transforming growth factor-beta (TGF-beta) receptor superfamily [UniProt: P41594]. It functions by binding bone morphogenetic proteins (BMPs), which induces the formation of a heteromeric signaling complex with type I receptors to activate downstream SMAD1/5/8 transcription factors. This signaling pathway is essential for maintaining vascular homeostasis, specifically by regulating the proliferation, survival, and apoptosis of pulmonary artery smooth muscle and endothelial cells. Mutations in the BMPR2 gene, particularly loss-of-function mutations, are the primary genetic cause of hereditary pulmonary arterial hypertension (PAH), leading to pathological vascular remodeling and increased pulmonary vascular resistance. Beyond its role in the vasculature, BMPR2 is involved in bone development and has been implicated in the progression of various cancers, such as colorectal and prostate cancer, where it often acts as a tumor suppressor. Therapeutic strategies targeting this pathway include the use of ligand traps like sotatercept, which sequester activins and growth differentiation factors to restore the balance between BMP and TGF-beta signaling. Other approaches under investigation include small molecule activators like tacrolimus that enhance residual BMPR2 signaling or gene therapies aimed at restoring receptor expression in the pulmonary vasculature.
Sotatercept acts as a ligand trap for activins and growth differentiation factors, thereby reducing signaling through ActRIIA/B and restoring the balance with the impaired BMPR2 pathway. Tacrolimus (FK506) acts as a small molecule activator that enhances BMPR2-mediated SMAD signaling by binding to FKBP12, which normally inhibits the receptor.
2 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bone morphogenetic protein receptor type 2 (BMPR2) (BMPR2).